Amgen Urges Ban On Cholesterol Drug Sales After Patent Win
Amgen Inc. urged a Delaware federal judge to levy a permanent injunction barring Sanofi SA and Regeneron Pharmaceuticals Inc. from selling cholesterol drug Praluent after a jury found Amgen's patents for...To view the full article, register now.
Already a subscriber? Click here to view full article